Vol 50 No 03

PARP inhibitor niraparib shows promise in mCRPC with DNA repair gene defects

February 10, 2022

“Such findings underscore the need for and importance of molecular testing to inform management along with continued research to establish treatment paradigms with appropriately targeted therapies for patients with prostate cancer,” the authors wrote.

Gender disparities found in bladder cancer trials and real-world systemic therapy use

February 08, 2022

“We have to be more mindful and thoughtful about the fact that certain populations are underrepresented in clinical trials, and that’s likely due to a number of factors,” said co-author Padraic O’Malley, MD, MSc, FRCSC.